PresentationsUniversal Expansion of CBL-B–inhibited Tumor-Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation By AldenMC Production / November 10, 2022
PresentationsA Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies By AldenMC Production / November 10, 2022
PresentationsInitial Clinical Characterization of Novel Proximal Biomarkers for NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies By AldenMC Production / November 10, 2022
PresentationsA Novel Small Molecule Inhibitor of CBL-B Shows Potent Antitumor Activity in Combination with Pmel-1 Adoptive Cell Transfer in an Aggressive Mouse Melanoma Model By AldenMC Production / November 10, 2022
PresentationsDiscovery of Orally Active, Brain-Penetrant, Targeted Protein Degraders By AldenMC Production / October 26, 2022
PresentationsUtilizing DEL as a Primary Discovery Engine for Targeted Protein Degradation By AldenMC Production / October 26, 2022
PresentationsThe First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic By AldenMC Production / October 26, 2022
PresentationsCombining TIL with Small Molecule Inhibitors to Enhance T-Cell Expansion & Phenotypes By AldenMC Production / October 25, 2022
PresentationsNX-1607, an inhibitor of the CBL-B E3 ubiquitin ligase, promotes favorable local and systemic changes in infiltrating immune cells in multiple mouse tumor models By AldenMC Production / September 30, 2022
